Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  CVS Health Corporation    CVS


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Health Executives Brace for Change In Regulation and Competition -- WSJ

share with twitter share with LinkedIn share with facebook
share via e-mail
01/17/2020 | 02:48am EST

By Anna Wilde Mathews and Peter Loftus

The annual J.P. Morgan health care conference is taking place this week in San Francisco. Here are some of the hot topics under discussion at the four-day event, which wraps up Thursday.

Politics Looms Too Large

Investors are overreacting to political developments, Centene Corp. CEO Michael Neidorff said in a Wednesday interview during the conference, and added that he is "beyond surprised" at how shares of managed-care companies have been moving around due to news related to the presidential campaign.

"There is no rational reason to let a Des Moines Register poll" affect investment decisions in the sector, he said. Mr. Neidorff said the U.S. can't afford a single-payer government health-care system and he doesn't expect one to be enacted.

"Single payers control cost by limiting access," he said. "All we're talking about with Medicare for All is politics, we're not talking about good policy."

Congress Could Act on Drug Prices

The pharmaceutical industry's top U.S. lobbyist sees signs that Congress could agree on legislation to reduce drug costs this year, potentially in May when certain government health funding expires and is up for renewal.

Steve Ubl, president of the Pharmaceutical Research and Manufacturers of America, said there are areas of overlap between certain drug-price bills in the Democratic-controlled House and a bipartisan bill that passed the Senate Finance Committee last year.

"To be honest, we don't love every aspect of every one of these bills, but if Congress wants to act on drug pricing, the contours of an agreement are there," Mr. Ubl said during a panel discussion at the conference on Tuesday. "The real question is whether politics will supersede the discussion."

The trade group, known as PhRMA, opposes provisions of a House bill that gives the federal Medicare program power to negotiate drug prices and cap U.S. prices at a percentage of foreign prices. But PhRMA supports provisions that cap patients' out-of-pocket costs for drugs.

J&J Sees Price Pressure

Johnson & Johnson says it is counting on prescription volume growth rather than price hikes to fuel U.S. sales growth in its pharmaceutical unit.

While J&J has raised U.S. list prices for some of its drugs, average net prices -- those J&J realizes after paying rebates and discounts -- have declined in the past couple of years.

"I don't see pricing getting easier," Jennifer Taubert, head of J&J's pharmaceuticals unit, said at the conference on Monday.

Cigna, Oscar Plan a Plan

Cigna Corp. and Oscar Insurance Corp. will launch their joint small-business insurance plan in a handful of markets by the start of next year, Oscar CEO Mario Schlosser said in an interview.

The product will first roll out around the third quarter of 2020, he said, and "my hope would be, over time, we can go into all the markets."

Cigna isn't taking a stake in Oscar, he said, though the two companies will share risk on the new product, which will use Cigna's provider network relationships and Oscar's technology.

CVS Expanding Health Hubs

CVS Health Corp. says it has around 50 of its new health hub stores open, in markets including Philadelphia, and aims for more than 600 by the end of this year.

The company doesn't disclose the hub stores' profitability, but says it has seen increased front-store sales, greater customer engagement and greater pharmacy penetration.

"That is what is giving us the confidence to move with the rapid rollout, " CEO Larry Merlo said. The company says it will offer more financial detail once it has a critical mass of stores, this summer.

Lilly Injects New Thinking

A year ago, Eli Lilly & Co. struck a deal to acquire cancer-drug developer Loxo Oncology Inc. for $8 billion. Recently Lilly took the unusual step of putting Loxo executives in charge of Lilly's oncology research.

More typically, a biotech's leadership departs after being bought by a larger company. But in Lilly's case, "in a 145-year-old company, it helps to inject new thinking, new people," Lilly's R&D chief, Daniel Skovronsky said on the sidelines of the conference. He said the move will allow Lilly to be more agile in developing cancer drugs.

BD Doesn't Expect Big Deals

Medical-supplies giant Becton, Dickinson and Co. has no near-term plans for another major acquisition on the scale of its purchases of CareFusion Corp. and C.R. Bard Inc. in recent years.

Instead, once BD pays down debt from the $24 billion Bard deal to a certain level, "we'll redirect a large amount" of the freed-up cash flow for smaller, "tuck-in" deals, incoming CEO Tom Polen told The Wall Street Journal on the sidelines of the conference.

Write to Anna Wilde Mathews at anna.mathews@wsj.com and Peter Loftus at peter.loftus@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
BECTON, DICKINSON AND COMPANY 0.03% 256.07 Delayed Quote.-5.85%
CENTENE CORPORATION 0.99% 67.37 Delayed Quote.6.11%
CIGNA CORPORATION -0.23% 221.44 Delayed Quote.8.54%
CVS HEALTH CORPORATION -0.31% 71.78 Delayed Quote.-3.38%
ELI LILLY AND COMPANY -0.13% 140.83 Delayed Quote.7.15%
JOHNSON & JOHNSON -0.13% 148.94 Delayed Quote.2.24%
share with twitter share with LinkedIn share with facebook
share via e-mail
02/18CVS HEALTH : Management's Discussion and Analysis of Financial Condition and Res..
02/14CVS HEALTH : RespireRx Pharmaceuticals CEO Issues Progress and Status Report
02/13CVS HEALTH : Aetna Medicaid Launches New Approach To Integrated Care Supporting ..
02/13CVS Reaps Benefits of Aetna Deal -- WSJ
02/13CVS HEALTH : pharmacy business lifted by high prices
02/12CVS HEALTH : Business Highlights
02/12Health Care Up As Investors Hedge On Chances Of Coronavirus Cure -- Health Ca..
02/12CVS Swings to Profit, Forecasts 2020 Results in Line With Estimates -- Update
02/12GLOBAL MARKETS LIVE: Boeing gets 0 orders in January, Lyft won’t be profitabl..
02/12CVS HEALTH : Q4 2019 Earnings Presentation
More news
Financials (USD)
Sales 2020 263 B
EBIT 2020 15 728 M
Net income 2020 7 271 M
Debt 2020 55 418 M
Yield 2020 2,79%
P/E ratio 2020 12,9x
P/E ratio 2021 11,6x
EV / Sales2020 0,57x
EV / Sales2021 0,53x
Capitalization 93 613 M
Duration : Period :
CVS Health Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CVS HEALTH CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 84,19  $
Last Close Price 71,78  $
Spread / Highest target 51,9%
Spread / Average Target 17,3%
Spread / Lowest Target -1,09%
EPS Revisions
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
Eva C. Boratto Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President